Exclusive Summary

• - US-registered voriconazole oral suspension (40 mg/mL, 75 mL) fits pediatrics and dysphagic patients, enabling fast distribution partnerships.
• - Originator patents expired; generics are mature globally, but oral suspension suppliers remain fewer, offering a differentiated entry.
• - WHO and IDSA/ECMM list voriconazole as first-line for invasive aspergillosis, addressing high-mortality invasive fungal infections.
• - Around 300,000 invasive aspergillosis and 700,000+ candidemia cases annually worldwide, with growing transplant/oncology/ICU populations sustaining demand.
• - Typically 60–85% cheaper than the originator, and US registration plus compliance data facilitate market access and tender negotiations.